Clinical trial
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
NCT00004081 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00004081 |
|---|---|
| Title | Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | docetaxel |
| Enrollment | 30 |
| Start date | Jul 1, 1999 |
| Primary completion | Jan 1, 2002 |
| Completion | Mar 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: